HSA
HAE icon

Hussman Strategic Advisors’s Haemonetics HAE Stock Holding History

Hussman Strategic Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Buy
+10,500
New +$684K 0.13% 234
2025
Q4 		– Sell
-10,500
Closed -$512K – 305
2025
Q3 		$512K Buy
+10,500
New +$650K 0.11% 240

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hussman Strategic Advisors's HAE Position: Q1 2026 in Review

Hussman Strategic Advisors opened a new position in Haemonetics (HAE) in Q1 2026: 10,500 shares worth $592K. The stake represents 0.13% of the portfolio and ranks #234 among its holdings. This is a return to the name: Hussman Strategic Advisors previously reported a position in HAE as recently as Q3 2025.

Hussman Strategic Advisors first reported a position in HAE in Q3 2025 and has held it in 2 quarters since. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Hussman Strategic Advisors held 10,500 shares of Haemonetics worth $592K as of Q1 2026.
  • Haemonetics was a new Hussman Strategic Advisors position in Q1 2026.
  • Haemonetics made up 0.13% of Hussman Strategic Advisors's portfolio in Q1 2026, its #234 holding.
  • Hussman Strategic Advisors first reported a position in Haemonetics in Q3 2025 and has held it in 2 quarters since.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.